System provides interventional cardiologists with the first and only clinically proven treatment beyond percutaneous coronary intervention (PCI) to significantly reduce muscle damage in heart attack patients.
The second-generation TherOx System provides SuperSaturated Oxygen (SSO2) Therapy and reduces heart muscle damage in “widowmaker” heart attack patients.
The HFAMS sensor is non-invasive and can be worn by patients 24 hours a day. ZOLL HFAMS continuously records, stores, and transmits patient data, including Thoracic Fluid Index, heart rate, respiration rate, activity, posture, and heart rhythm (ECG).
3/1/18: ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today that findings from the “Vest Prevention of Early Sudden Death Trial” (VEST Trial) on use of the ZOLL LifeVest® wearable cardioverter defibrillator (WCD) will be presented as a Late-Breaking Clinical Trial at the American College of Cardiology’s 67th Annual Scientific Session on Saturday, March 10, 2018 in Orlando, Florida. Results will be presented by Jeffrey E. Olgin, MD, FACC, co-principal investigator, Professor and Chief of Cardiology, University of California San Francisco Heart and Vascular Center.
AHA/ACC/HRS Publish New Guidelines on the Wearable Cardioverter Defibrillator for Patients at Risk of Sudden Cardiac Death
The American Heart Association (AHA), American College of Cardiology (ACC), and Heart Rhythm Society (HRS) have issued guidelines for the wearable cardioverter defibrillator (WCD) that include recommended use for a wide range of patients at risk of sudden cardiac death (SCD), including those who have recently suffered a myocardial infarction (MI), with or without revascularization, and those with a newly diagnosed non-ischemic dilated cardiomyopathy.